ASCO GI 2023 | daNIS-2: NIS793 with nab-paclitaxel and gemcitabine in mPDAC

Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, discusses patient reported outcomes and biomarkers in the Phase III daNIS-2 trial (NCT04935359) of NIS793, an anti-TGF-β monoclonal antibody, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients with treatment-naïve mPDAC were recruited and were either given NIS793 with nab-paclitaxel and gemcitabine (NG), or with NG alone. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.